{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil","slug":"vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil","published_at":"2026-07-08T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/296dbeabb7a5553c79e61442d4a88f512b65663f9d12071c7efc2033f8b4bd77/eyJlcGlzb2RlSWQiOiJlNmM5N2FhZi1iN2QyLTQzNTgtOGQ2NC02YTRjZTBjY2JlZmQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0ZDQ4MjllMThiYTBmOTljZDljNWFlL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTdfXzIwLTQwLTQxLm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/296dbeabb7a5553c79e61442d4a88f512b65663f9d12071c7efc2033f8b4bd77/eyJlcGlzb2RlSWQiOiJlNmM5N2FhZi1iN2QyLTQzNTgtOGQ2NC02YTRjZTBjY2JlZmQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE0ZDQ4MjllMThiYTBmOTljZDljNWFlL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTdfXzIwLTQwLTQxLm1wMyJ9.mp3","summary":"A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.","meta_description":"A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IP…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1024,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/vertex-carries-m-a-uptick-into-h2-ipos-and-vc-raises-also-grow-fda-on-pace-despite-turmoil.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}